Asarina Pharma AB (publ) Q1 Report 2021 released
Asarina Pharma CEO Peter Nordkild: “The first quarter 2021 has been busy and exciting. We are moving decisively towards completing our Menstrual Migraine phase IIa study with the last patient’s last visit on April 8. We are on schedule to publish topline results for the study before the end of June. In Tourette Syndrome we have finalized all preclinical studies and added an additional test center to the upcoming Phase IIa clinical study.”
FINANCIAL HIGHLIGHTS
- Cost reduction results in low expenditure in all areas.
- Solid cash position at the end of 1st quarter.
R&D HIGHLIGHTS
MENSTRUAL MIGRAINE
- Last patient last visit in the Phase IIa Study took place on April 8.
- Data cleaning is ongoing.
- We are on schedule to publish topline results before the end of June.
TOURETTE SYNDROME
- Preclinical studies completed without findings
- CTA submitted to the Danish Medical Agency on March 21.
- We expect to receive an approval in May and to initiate the study shortly thereafter.
For further information, please contact:
Peter Nordkild, CEO
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified Adviser
Erik Penser Bank AB
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se
About Asarina Pharma
We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.
The information above was provided by the CEO of Asarina Pharma AB (publ), for publication on May 18, 08.00, 2021.
Tags: